Antimicrobial resistance, particularly among multidrug-resistant Gram-negative bacteria like Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacterales, is eroding the effectiveness of standard treatments and leaving clinicians with limited therapeutic options.

As we face narrowing treatment options, the challenge is no longer just identifying viable antibiotics but ensuring precise antimicrobial susceptibility testing (AST) to guide informed choices.

For AST, some challenging antimicrobials include:

• Inhibitor combination drugs: New β-lactam/β-lactamase inhibitor combination agents like meropenem-vaborbactam, imipenem-relebactam, and the monobactam-inhibitor combination aztreonam-avibactam target specific resistance enzymes, but require careful testing due to variable enzyme activity, co-produced resistance mechanisms, and sensitivity to inoculum concentration and drug/inhibitor ratios.
  
• Colistin: As a last-resort therapy option, colistin poses a challenge for AST due to poor agar diffusion and plastic binding properties.

To overcome these challenges, an accurate minimum inhibitory concentration (MIC) result derived from a wide dilution range of antibiotic concentrations, tested by a broth microdilution method, remains the method of choice for the most common and complex AST. The Thermo Scientific™ Sensititre™ AST System delivers reliable MIC testing to help guide patient-specific dosing and support improved patient outcomes, and promote antimicrobial stewardship.

Please select the Sensititre Plate Guide for your region below.

For more information on the Sensititre System, visit thermofisher.com/sensititre